Cisbio Certifies Beckman Coulter's PARADIGM™ Detection Platform for HTRF* Assays

Beckman Coulter, Inc. announced today that Cisbio International has awarded its homogenous time-resolved fluorescence (HTRF*) certification to the PARADIGM™ Detection Platform. Cisbio's certification verifies that the detection platform meets or exceeds performance criteria for HTRF assays. A new HTRF detection cartridge is now available for the unique, modular PARADIGM platform, bringing the growing total selection to 10. These detection cartridges can be interchanged in less than five minutes to meet different assay needs.

PARADIGM, introduced earlier this year, is the first user-upgradeable and -configurable multimode reader. It is ideal for labs with multiple users and applications. The high-throughput detector reads on the fly, in formats from 6 to 1,536 wells.

Cisbio's patented HTRF technology is incorporated into a growing selection of assays and reagents for drug discovery and screening. These popular assays produce superior results and are easily miniaturized and automated.

"Beckman Coulter's application-focused, multifunctional detectors are very highly regarded and we are delighted that they have added an HTRF detection cartridge," commented François Degorce, head of HTRF marketing and business development at Cisbio.

"This partnership with Cisbio is a great example of the flexibility that makes PARADIGM unique and successful," explained Jim Barry, marketing manager for Beckman Coulter. "Detection modes are difficult and costly to add to other multimode detectors once the systems are installed. Our detection cartridge system maximizes the users' return on investment and our instruments and automation platforms are already well-established in drug discovery and screening labs, where the use of TR-FRET assays, specifically HTRF are growing."